title: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
abstract: A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
authors.affiliation: Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Petrioli
authors.forename: M
authors.initials: M
authors.lastname: Sabatino
authors.forename: A I
authors.initials: AI
authors.lastname: Fiaschi
authors.forename: S
authors.initials: S
authors.lastname: Marsili
authors.forename: D
authors.initials: D
authors.lastname: Pozzessere
authors.forename: S
authors.initials: S
authors.lastname: Messinese
authors.forename: P
authors.initials: P
authors.lastname: Correale
authors.forename: S
authors.initials: S
authors.lastname: Civitelli
authors.forename: G
authors.initials: G
authors.lastname: Tanzini
authors.forename: F
authors.initials: F
authors.lastname: Tani
authors.forename: A
authors.initials: A
authors.lastname: De Martino
authors.forename: G
authors.initials: G
authors.lastname: Marzocca
authors.forename: M
authors.initials: M
authors.lastname: Lorenzi
authors.forename: G
authors.initials: G
authors.lastname: Giorgi
authors.forename: G
authors.initials: G
authors.lastname: Francini
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005641:Tegafur; D014498:Uracil; D000077146:Irinotecan; D002955:Leucovorin; D002166:Camptothecin